Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: CD26 antigen antagonists - DARA BioSciences

Next Previous
Search
Drug Profile

Research programme: CD26 antigen antagonists - DARA BioSciences

Alternative Names: DB 040; DB 160; DB 295; Dipeptidyl peptidase IV inhibitors - DARA BioSciences; DPP-IV inhibitors

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DARA Biosciences
  • Developer Fortovia Therapeutics
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 15 Feb 2012 Research programme: CD26 antigen antagonists - DARA BioSciences is available for licensing as of 15 Feb 2012. http://www.darabio.com
  • 17 Jan 2012 DARA BioSciences has identified DB 160 as a preclinical candidate for future development and monetisation
  • 02 Aug 2007 Preclinical trials in Type-2 diabetes mellitus in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top